Article Text

Download PDFPDF
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis
  1. A Petzold1,2,
  2. S Pittock3,4,
  3. V Lennon3,4,5,
  4. C Maggiore2,
  5. B G Weinshenker3,
  6. G T Plant2,6,7
  1. 1
    Department of Neuroinflammation, Institute of Neurology, University College London, London, UK
  2. 2
    National Hospital for Neurology and Neurosurgery, London, UK
  3. 3
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
  4. 4
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
  5. 5
    Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
  6. 6
    Moorfields Eye Hospital, Department of Neuro-ophthalmology, London, UK
  7. 7
    Medical Eye Unit, St Thomas’ Hospital, London, UK
  1. Correspondence to Dr A Petzold, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; a.petzold{at}


The clinical course of immune mediated optic neuritis (ON) will depend on the specific underlying inflammatory disease. These disorders have traditionally been classified according to clinical and MRI findings. Aquaporin-4 (AQP4) autoantibodies (neuromyelitis optica-IgG (NMO-IgG)) may have diagnostic and prognostic value in patients who present with isolated ON. In this prospective study, NMO-IgG was evaluated in 114 patients with ON in the following contexts: neuromyelitis optica (NMO), multiple sclerosis (MSON), chronic relapsing inflammatory ON (CRION), relapsing isolated ON (RION) and single isolated ON (SION). The proportion seropositive was 56% for NMO (n = 9), 0% for MSON (n = 28) and 5% for the remaining diagnostic categories (CRION (n = 19), RION (n = 17) and SION (n = 41)). Testing for NMO-IgG in patients with recurrent or severe ON who lack convincing evidence of MS may identify patients who would benefit from immunosuppression rather than MS directed immunomodulatory therapies.

View Full Text

Statistics from


  • Competing interests VAL and BW have intellectual property associated with the discovery of NMO-IgG, which has been licensed to a commercial entity. The NMO-IgG test is offered on a service basis by Mayo Collaborative Service Inc, an agency of the Mayo Foundation.

  • Ethics approval The study was approved by the local and national ethics committees.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.